COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONS

Skin and soft tissue infections are one of the most common nosocomial infections, which are caused most often by gram-positive bacteria (staphylococci, streptococci, enterococci) with multiple drug resistance. These infections are among the major nosocomial infections in oncology clinics along with...

Full description

Saved in:
Bibliographic Details
Main Authors: N. V. Dmitrieva, I. N. Petuhova, Z. V. Grigorievskaya, N. S. Bagirova, I. V. Tereshchenko
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2018-11-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/863
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849408375458103296
author N. V. Dmitrieva
I. N. Petuhova
Z. V. Grigorievskaya
N. S. Bagirova
I. V. Tereshchenko
author_facet N. V. Dmitrieva
I. N. Petuhova
Z. V. Grigorievskaya
N. S. Bagirova
I. V. Tereshchenko
author_sort N. V. Dmitrieva
collection DOAJ
description Skin and soft tissue infections are one of the most common nosocomial infections, which are caused most often by gram-positive bacteria (staphylococci, streptococci, enterococci) with multiple drug resistance. These infections are among the major nosocomial infections in oncology clinics along with respiratory and urinary tract infections, blood flow infections, febrile neutropenia, and fevers of unknown origin.The purpose of the study was to compare the clinical activity of two oxazolidinones: linezolid and tedizolide in patients with skin and soft tissue infections.Material and methods. We analyzed recent publications and data available in websites: rlsnet.ru, eucast.org, and medlux.ru.Results. Clinical trials showed that both oxazolidinones were comparable in clinical efficacy, microbiological activity, and incidence of side effects in skin and soft tissue infections caused by various resistant gram-positive microorganisms: methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Streptococcus faecalis (VRE), as well as certain streptococci. The treatment regimen of tedizolide (200 mg once daily for 6 days) was compared with linezolid regimen (600 mg twice daily for 10 days). No comparisons were made with the 6-day linezolid regimen, although the authors concluded that shorter duration of treatment with tadizolide resulted in an equal effect. In addition, the minimum inhibitory concentrations (MICs) obtained by comparing the microbiological activity of these two agents showed the advantage of tedizolide against certain strains. However, the comparison was not made according to the EUCAST standards (Committee on Antimicrobial Susceptibility Testing). Concerning the cost of both drugs, treatment with linezolidom was 2-3 times cheaper than treatment with tidezolid, even with its shorter course.Conclusion. Thus, tedisolide was equally effective for linezolid. Data on the microbiological sensitivity of linezolid can be extrapolated to tedizolide in the absence of testing in laboratories. However, lower financial costs and wider range of microbiological activity make linezolid the drug of choice for the treatment of skin and soft tissue infections caused by resistant gram-positive microorganisms.
format Article
id doaj-art-7357ffcf46dc433b84c8b6f8c89926f6
institution Kabale University
issn 1814-4861
2312-3168
language Russian
publishDate 2018-11-01
publisher Russian Academy of Sciences, Tomsk National Research Medical Center
record_format Article
series Сибирский онкологический журнал
spelling doaj-art-7357ffcf46dc433b84c8b6f8c89926f62025-08-20T03:35:48ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682018-11-01175879310.21294/1814-4861-2018-17-5-87-93581COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONSN. V. Dmitrieva0I. N. Petuhova1Z. V. Grigorievskaya2N. S. Bagirova3I. V. Tereshchenko4N.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologySkin and soft tissue infections are one of the most common nosocomial infections, which are caused most often by gram-positive bacteria (staphylococci, streptococci, enterococci) with multiple drug resistance. These infections are among the major nosocomial infections in oncology clinics along with respiratory and urinary tract infections, blood flow infections, febrile neutropenia, and fevers of unknown origin.The purpose of the study was to compare the clinical activity of two oxazolidinones: linezolid and tedizolide in patients with skin and soft tissue infections.Material and methods. We analyzed recent publications and data available in websites: rlsnet.ru, eucast.org, and medlux.ru.Results. Clinical trials showed that both oxazolidinones were comparable in clinical efficacy, microbiological activity, and incidence of side effects in skin and soft tissue infections caused by various resistant gram-positive microorganisms: methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Streptococcus faecalis (VRE), as well as certain streptococci. The treatment regimen of tedizolide (200 mg once daily for 6 days) was compared with linezolid regimen (600 mg twice daily for 10 days). No comparisons were made with the 6-day linezolid regimen, although the authors concluded that shorter duration of treatment with tadizolide resulted in an equal effect. In addition, the minimum inhibitory concentrations (MICs) obtained by comparing the microbiological activity of these two agents showed the advantage of tedizolide against certain strains. However, the comparison was not made according to the EUCAST standards (Committee on Antimicrobial Susceptibility Testing). Concerning the cost of both drugs, treatment with linezolidom was 2-3 times cheaper than treatment with tidezolid, even with its shorter course.Conclusion. Thus, tedisolide was equally effective for linezolid. Data on the microbiological sensitivity of linezolid can be extrapolated to tedizolide in the absence of testing in laboratories. However, lower financial costs and wider range of microbiological activity make linezolid the drug of choice for the treatment of skin and soft tissue infections caused by resistant gram-positive microorganisms.https://www.siboncoj.ru/jour/article/view/863linezolidtedizolidecomparison of linezolid and tedizolideskin and soft tissue infectionscancer patientsvancomycin-resistant streptococcus faecalismethicillin-resistant staphylococcus aureus
spellingShingle N. V. Dmitrieva
I. N. Petuhova
Z. V. Grigorievskaya
N. S. Bagirova
I. V. Tereshchenko
COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONS
Сибирский онкологический журнал
linezolid
tedizolide
comparison of linezolid and tedizolide
skin and soft tissue infections
cancer patients
vancomycin-resistant streptococcus faecalis
methicillin-resistant staphylococcus aureus
title COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONS
title_full COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONS
title_fullStr COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONS
title_full_unstemmed COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONS
title_short COMPARISON OF THE CLINICAL ACTIVITY OF TWO OXAZOLIDINONES – LINEZOLID AND TEDIZOLIDE: UNJUSTIFIED EXPECTATIONS
title_sort comparison of the clinical activity of two oxazolidinones linezolid and tedizolide unjustified expectations
topic linezolid
tedizolide
comparison of linezolid and tedizolide
skin and soft tissue infections
cancer patients
vancomycin-resistant streptococcus faecalis
methicillin-resistant staphylococcus aureus
url https://www.siboncoj.ru/jour/article/view/863
work_keys_str_mv AT nvdmitrieva comparisonoftheclinicalactivityoftwooxazolidinoneslinezolidandtedizolideunjustifiedexpectations
AT inpetuhova comparisonoftheclinicalactivityoftwooxazolidinoneslinezolidandtedizolideunjustifiedexpectations
AT zvgrigorievskaya comparisonoftheclinicalactivityoftwooxazolidinoneslinezolidandtedizolideunjustifiedexpectations
AT nsbagirova comparisonoftheclinicalactivityoftwooxazolidinoneslinezolidandtedizolideunjustifiedexpectations
AT ivtereshchenko comparisonoftheclinicalactivityoftwooxazolidinoneslinezolidandtedizolideunjustifiedexpectations